UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

The identification and characterization of the marine natural product scytonemin as a novel antiproliferative pharmacophore

The Journal of pharmacology and experimental therapeutics, 2002-11, Vol.303 (2), p.858-866

2002

Volltextzugriff (PDF)

The human polo-like kinase, PLK, regulates cdc2/cyclin B through phosphorylation and activation of the cdc25C phosphatase

Cellular signalling, 2000-06, Vol.12 (6), p.405-411

2000

Volltextzugriff (PDF)

Regulation of TNF‐α and IFN‐γ induced CXCL10 expression: participation of the airway smooth muscle in the pulmonary inflammatory response in chronic obstructive pulmonary disease

The FASEB journal, 2004-01, Vol.18 (1), p.191-193

2004

Volltextzugriff (PDF)

Human Calcium-independent Phospholipase A2 Mediates Lymphocyte Proliferation

The Journal of biological chemistry, 2000-11, Vol.275 (46), p.35692-35698

2000

Volltextzugriff (PDF)

Small-molecule inhibitors of NF- κB for the treatment of inflammatory joint disease

Current Opinion in Pharmacology, 2002-06, Vol.2 (3), p.316-321

2002

Volltextzugriff (PDF)

Anti-human RP105 sera induces lymphocyte proliferation

Journal of leukocyte biology, 1999-01, Vol.65 (1), p.43-49

1999

Volltextzugriff (PDF)

Attenuation of Murine Collagen-Induced Arthritis by a Novel, Potent, Selective Small Molecule Inhibitor of IκB Kinase 2, TPCA-1 (2-[(Aminocarbonyl)amino]-5-(4-fluorophenyl)-3-thiophenecarboxamide), Occurs via Reduction of Proinflammatory Cytokines and Antigen-Induced T Cell Proliferation

The Journal of pharmacology and experimental therapeutics, 2005-01, Vol.312 (1), p.373-381

2005

Volltextzugriff (PDF)

Modulation of human monocyte activities by tranilast, SB 252218, a compound demonstrating efficacy in restenosis

The Journal of pharmacology and experimental therapeutics, 2000-12, Vol.295 (3), p.1061

2000

Volltextzugriff (PDF)

Manipulation of Distinct NFκB Proteins Alters Interleukin-1β-induced Human Rheumatoid Synovial Fibroblast Prostaglandin E2 Formation

The Journal of biological chemistry, 1996-12, Vol.271 (49), p.31496-31501

1996

Volltextzugriff (PDF)

Small-molecule inhibitors of NF-kappaB for the treatment of inflammatory joint disease

Current opinion in pharmacology, 2002-06, Vol.2 (3), p.316-321

2002

Volltextzugriff (PDF)

Attenuation of murine collagen-induced arthritis by a novel, potent, selective small molecule inhibitor of IkappaB Kinase 2, TPCA-1 (2-[(aminocarbonyl)amino]-5-(4-fluorophenyl)-3-thiophenecarboxamide), occurs via reduction of proinflammatory cytokines and antigen-induced T cell Proliferation

The Journal of pharmacology and experimental therapeutics, 2005-01, Vol.312 (1), p.373

2005

Volltextzugriff (PDF)

Manipulation of Distinct NFÎºB Proteins Alters Interleukin-1Î²-induced Human Rheumatoid Synovial Fibroblast Prostaglandin E2 Formation

The Journal of biological chemistry, 1996-12, Vol.271 (49), p.31496

1996

Volltextzugriff (PDF)

Utility of Oligonucleotides as Tools to Study the Function and Regulation of 85 kDa Phospholipase A 2

Antisense & nucleic acid drug development, 1998-04, Vol.8 (2), p.153-157

1998

Volltextzugriff (PDF)

Utility of oligonucleotides as tools to study the function and regulation of 85 kDa phospholipase A2

Antisense & nucleic acid drug development, 1998-04, Vol.8 (2), p.153-157

1998

Volltextzugriff (PDF)

Evidence that 85kDa phospholipase A2 is not linked to CoA-independent transacylase-mediated production of platelet-activating factor in human monocytes

Biochimica et biophysica acta. Lipids and lipid metabolism, 1997-06, Vol.1346 (2), p.173-184

1997

Volltextzugriff (PDF)

Evidence that 85 kDa phospholipase A 2 is not linked to CoA-independent transacylase-mediated production of platelet-activating factor in human monocytes

Biochimica et biophysica acta. Lipids and lipid metabolism, 1997, Vol.1346 (2), p.173-184

1997

Volltextzugriff (PDF)

Amivantamab plus lazertinib in osimertinib-relapsed EGFR-mutant advanced non-small cell lung cancer: a phase 1 trial

Nature medicine, 2023-10, Vol.29 (10), p.2577-2585

2023

Volltextzugriff (PDF)

Management of infusion-related reactions (IRRs) in patients receiving amivantamab in the CHRYSALIS study

Lung cancer (Amsterdam, Netherlands), 2023-04, Vol.178, p.166-171

2023

Volltextzugriff (PDF)

Amivantamab in combination with lazertinib for the treatment of osimertinib-relapsed, chemotherapy-naïve EGFR mutant (EGFRm) non-small cell lung cancer (NSCLC) and potential biomarkers for response

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.9006-9006

2021

Volltextzugriff (PDF)

Amivantamab (JNJ-61186372), an anti-EGFR-MET bispecific antibody, in patients with EGFR exon 20 insertion (exon20ins)-mutated non-small cell lung cancer (NSCLC)

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.9512-9512

2020

Volltextzugriff (PDF)

Cytosolic 85-kDa Phospholipase A2-mediated Release of Arachidonic Acid Is Critical for Proliferation of Vascular Smooth Muscle Cells

The Journal of biological chemistry, 1997-11, Vol.272 (48), p.30504-30511

1997

Volltextzugriff (PDF)

Characterization of phospholipase A2 from human nasal lavage

American journal of respiratory cell and molecular biology, 1994-07, Vol.11 (1), p.108-113

1994

Volltextzugriff (PDF)

A novel NF-κB activation inhibitor blocks inflammatory mediator production and disease severity in the dextran sulfate (DSS) model of mouse colitis

Gastroenterology (New York, N.Y. 1943), 2001-04, Vol.120 (5), p.A690-A690

2001

Volltextzugriff (PDF)

1 – 24 von 24

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(20)
Mit Volltextzugriff
(18)

Publikationsform

Artikel
(24)

Sprache

Englisch
(24)
Japanisch
(3)

Erscheinungsjahr

n.n

Menü

Weitere Dienste

Einstellungen

The identification and characterization of the marine natural product scytonemin as a novel antiproliferative pharmacophore

The human polo-like kinase, PLK, regulates cdc2/cyclin B through phosphorylation and activation of the cdc25C phosphatase

Regulation of TNF‐α and IFN‐γ induced CXCL10 expression: participation of the airway smooth muscle in the pulmonary inflammatory response in chronic obstructive pulmonary disease

Human Calcium-independent Phospholipase A2 Mediates Lymphocyte Proliferation

Small-molecule inhibitors of NF- κB for the treatment of inflammatory joint disease

Anti-human RP105 sera induces lymphocyte proliferation

Attenuation of Murine Collagen-Induced Arthritis by a Novel, Potent, Selective Small Molecule Inhibitor of IκB Kinase 2, TPCA-1 (2-[(Aminocarbonyl)amino]-5-(4-fluorophenyl)-3-thiophenecarboxamide), Occurs via Reduction of Proinflammatory Cytokines and Antigen-Induced T Cell Proliferation

Modulation of human monocyte activities by tranilast, SB 252218, a compound demonstrating efficacy in restenosis

Manipulation of Distinct NFκB Proteins Alters Interleukin-1β-induced Human Rheumatoid Synovial Fibroblast Prostaglandin E2 Formation

Small-molecule inhibitors of NF-kappaB for the treatment of inflammatory joint disease

Attenuation of murine collagen-induced arthritis by a novel, potent, selective small molecule inhibitor of IkappaB Kinase 2, TPCA-1 (2-[(aminocarbonyl)amino]-5-(4-fluorophenyl)-3-thiophenecarboxamide), occurs via reduction of proinflammatory cytokines and antigen-induced T cell Proliferation

Manipulation of Distinct NFÎºB Proteins Alters Interleukin-1Î²-induced Human Rheumatoid Synovial Fibroblast Prostaglandin E2 Formation

Utility of Oligonucleotides as Tools to Study the Function and Regulation of 85 kDa Phospholipase A 2

Utility of oligonucleotides as tools to study the function and regulation of 85 kDa phospholipase A2

Evidence that 85kDa phospholipase A2 is not linked to CoA-independent transacylase-mediated production of platelet-activating factor in human monocytes

Evidence that 85 kDa phospholipase A 2 is not linked to CoA-independent transacylase-mediated production of platelet-activating factor in human monocytes

Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study

Amivantamab plus lazertinib in osimertinib-relapsed EGFR-mutant advanced non-small cell lung cancer: a phase 1 trial

Management of infusion-related reactions (IRRs) in patients receiving amivantamab in the CHRYSALIS study

Amivantamab in combination with lazertinib for the treatment of osimertinib-relapsed, chemotherapy-naïve EGFR mutant (EGFRm) non-small cell lung cancer (NSCLC) and potential biomarkers for response

Amivantamab (JNJ-61186372), an anti-EGFR-MET bispecific antibody, in patients with EGFR exon 20 insertion (exon20ins)-mutated non-small cell lung cancer (NSCLC)

Cytosolic 85-kDa Phospholipase A2-mediated Release of Arachidonic Acid Is Critical for Proliferation of Vascular Smooth Muscle Cells

Characterization of phospholipase A2 from human nasal lavage

A novel NF-κB activation inhibitor blocks inflammatory mediator production and disease severity in the dextran sulfate (DSS) model of mouse colitis

Suchergebnisse filtern